Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79810.820.0373%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Eupraxia Pharmaceuticals Inc

EPRXNASDAQ
Trade with Public
Trade with Public
$8.40
0.9012%
At close: Sep 4, 5:00 PM EST
$8.40
N/A
After Hours: Sep 4, 7:33 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

Eupraxia Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eupraxia Pharmaceuticals (EPRX).

Price Target Range — 5 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$16Upside to Avg. PT+92.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 26, 2026OppenheimerJay OlsonInitiateOutperform$17
May 21, 2026StifelAnnabel SamimyInitiateBuy$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17

Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
Benzinga Newsdesk

This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-ratings. Considering SAIL stock? Here's what analysts say.
Avi Kapoor

PRO
Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25

Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
Benzinga Newsdesk

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
Vandana Singh

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved